LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection. Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

For San Diego researchers and the wider immunotherapy community, the atlas functions as a practical roadmap. It does not ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...

CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...